TheranosticTrials.org

Clinical Trial · NCT02454010

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

Overview

The purpose of this study is to determine the safety and tolerability in subjects who receive FF-21101(111In) for dosimetry and FF-21101(90Y) for treatment of advanced solid tumors.

Sponsor

Actinium Pharmaceuticals, Inc

Phase

Phase 1

ClinicalTrials.gov

NCT02454010

Drug / Compound

FF-21101

Isotope(s):
Target(s):
  • CDH3 (Cadherin-3)
Ligand Class: Antibodies

FF-21101

Isotope(s):
Target(s):
  • CDH3 (Cadherin-3)
Ligand Class: Antibodies

Eligibility

Inclusion

  • Life expectancy of ≥ 3 months
  • At least one measurable disease site that meets target lesion requirements
  • Negative serum pregnancy test
  • Adequate hematologic parameters without ongoing transfusional support:
  • At least 4 weeks beyond the last chemotherapy (or ≥ 5 half-lives for targeted agents, whichever is shorter), radiotherapy, major surgery or experimental treatment and recovered from all acute toxicities (≤ Grade 1)
  • Archival tumor sample available, or be willing to undergo a fresh tumor biopsy, prior to study
  • Histologically or cytologically confirmed advanced solid tumor malignancy, refractory or relapsed from prior therapy, or for whom no alternative therapy is available
  • Adequate performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2

Exclusion

  • Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or confound the interpretation of study results
  • Serious cardiac condition within the last 6 months
  • Pregnant or breast-feeding
  • Corticosteroid use within 2 weeks of study treatment
  • Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, with the exception of antimicrobials that are considered to be essential for care of the patient
  • Active central nervous system (CNS) malignant disease in subjects with a history of CNS malignancy. Subjects with stable, prior, or currently treated brain metastases are allowed.
  • Known autoimmune disease
  • Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV)
  • History of retinal degenerative disease, history of uveitis, history of retinal vein occlusion (RVO), or any eye condition that would be considered a risk factor for RVO or has medically relevant abnormalities identified on screening ophthalmologic examination
  • Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ≥ 28 days has elapsed from last dose to study treatment.
  • Active infection requiring intravenous (IV) antibiotic usage within the last week prior to the dosimetry portion of the study
  • Prior radiation to \> 30% of the red marrow or to maximal tolerable level for any organ